No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A-T). In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively). In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established. (Current Controlled Trials, number ISRCTN08774933). © 2012 Movement Disorder Society.
A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia / Raffaella, Zannolli; Sabrina, Buoni; Gianni, Betti; Sara, Salvucci; Alessandro, Plebani; Annarosa, Soresina; Maria C., Pietrogrande; Silvana, Martino; Leuzzi, Vincenzo; Andrea, Finocchi; Roberto, Micheli; Livia Nicoletta, Rossi; Alfredo, Brusco; Filippo, Misiani; Alberto, Fois; Joseph, Hayek; Colleen, Kelly; Chessa, Luciana. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - ELETTRONICO. - 27:10(2012), pp. 1312-1316. [10.1002/mds.25126]
A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia
LEUZZI, Vincenzo;CHESSA, Luciana
2012
Abstract
No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A-T). In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively). In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established. (Current Controlled Trials, number ISRCTN08774933). © 2012 Movement Disorder Society.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
